Clinical Trial

Stockholm3 Test Validation in Men on Active Surveillance in Switzerland (CHAS3 Trial)

Study acronym: CHAS3
Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The CHAS3 trial studies whether the Stockholm3 blood test can reliably detect if prostate cancer becomes more aggressive in men who are being carefully monitored instead of treated right away (active surveillance). The goal is to see if this test can help doctors safely follow patients with fewer invasive procedures, such as repeated biopsies.
Protocol Amendment History 1 change
critical Primary endpoint(s) modified 2026-03-31
Trial Details
NCT Number NCT07478536
Lead Sponsor Insel Gruppe AG, University Hospital Bern
Conditions Prostate Cancer, Active Surveillance for Prostate Cancer
Enrollment 350 participants
Start Date 2026-07-01
Primary Completion 2028-03-31 (estimated)
Study Completion 2028-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-22